Share LinkedIn Email Copy Link The Biden administration on Thursday touted discounts of up to 79%, but many of these first 10 drugs are already sold well below list price.Read more about this post on Biospace
EndPoints Pfizer ends work on Sangamo’s hemophilia gene therapy, crushing biotech’s hopesDecember 31, 2024
EndPoints Despite mixed data in Alzheimer’s agitation, Axsome will still seek FDA approvalDecember 30, 2024